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Abstract
Persistent barriers to universal access to medicines are limited social protection in the event
of illness, inadequate financing for essential medicines, frequent stock-outs in the public
sector, and high prices in the private sector. We argue that greater coherence between
human rights law, national medicines policies, and universal health coverage schemes can
address these barriers. We present a cross-national content analysis of national medicines
policies from 71 countries published between 1990–2016. The World Health Organization’s
(WHO) 2001 guidelines for developing and implementing a national medicines policy and all
71 national medicines policies were assessed on 12 principles, linking a health systems
approach to essential medicines with international human rights law for medicines afford-
ability and financing for vulnerable groups. National medicines policies most frequently con-
tain measures for medicines selection and efficient spending/cost-effectiveness. Four
principles (legal right to health; government financing; efficient spending; and financial pro-
tection of vulnerable populations) are significantly stronger in national medicines policies
published after 2004 than before. Six principles have remained weak or absent: pooling
user contributions, international cooperation, and four principles for good governance. Over-
all, South Africa (1996), Indonesia and South Sudan (2006), Philippines (2011–2016),
Malaysia (2012), Somalia (2013), Afghanistan (2014), and Uganda (2015) include the most
relevant texts and can be used as models for other settings. We conclude that WHO’s 2001
guidelines have guided the content and language of many subsequent national medicines
policies. WHO and national policy makers can use these principles and the practical exam-
ples identified in our study to further align national medicines policies with human rights law
and with Target 3.8 for universal access to essential medicines in the Sustainable Develop-
ment Goals.
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Introduction
Universal access to essential medicines is an important component of the right to health and
the Sustainable Development Goals (SDGs). [1] Essential medicines are those required to meet
the priority health care needs of a population. [2] Realising universal access to medicines
requires a coherent approach to medicines as essential public goods. [3]
The World Health Organization (WHO) advocates for the adoption of a national medicines
policy (NMP) as a commitment to a goal and a guide to action. WHO’s 2001 guidelines to
Develop and implement a national drug policy elucidate the key components of a NMP. [4]
NMPs should be based on universal principles, involve a range of national stakeholders, and
be tailored to the local context. [4,5] The first NMPs were predominantly adopted by low- and
lower-middle income countries, and only since 2007 have many higher income countries fol-
lowed. [5,6] By 2015, over 90% of low and middle-income countries (LMICs) had published a
NMP. [6,7] Adopting a NMP has been associated with the provision of a basic range of essen-
tial medicines free at the point of care, and better quality use of medicines, particularly in
LMICs. [8] Some NMPs are associated with improved antibiotic use in low-resource settings.
[9] However, despite the development of NMPs in many countries, essential medicines have
often remained inaccessible to many, especially vulnerable populations.
Barriers to universal access
Most studies frame medicines as a single ‘input’ or commodity to be supplied in the health sys-
tem. [3] This view leads to fragmented policies and interventions that fail to address the sys-
tem-wide constraints (such as health care financing and medicine pricing) and consequently,
have a limited effect on medicines access for vulnerable groups. [3] Moreover, public policy in
many countries does not consistently recognise essential medicines as essential public goods,
nor is medicines accessibility seen as part of the progressive realisation of the right to health.
[10] This failure, among others, may be linked to stagnating public financing for medicines,
insufficient financial protection for patients, high medicines prices, and a general indifference
towards medicines inequities. [3,6,7,11,12] In response to these challenges, WHO promotes its
policies for essential medicines and health systems as tools to design and assess comprehensive
national strategies to achieve equitable and sustainable access to medicines. [2,4,13,14]
Public health policies and practices have changed since the turn of the century, which put
much more emphasis on human rights and promoting universal health coverage (UHC). We
therefore assert that greater coherence is now needed between NMPs’ goals and strategies, the
wider health system including UHC, and human rights; and that incorporating human rights
principles and the wider health systems perspective in NMPs can also create a supportive envi-
ronment for medicines affordability and financing for vulnerable groups.
The right to health emanates from international treaties, most notably the 1966 Interna-
tional Covenant on Economic, Social, and Cultural Rights (ICESCR), which is ratified by 165
States. [15] These governments therefore bear the irrevocable duty to protect and promote the
right to health. General Comment No. 14 (2000), an authoritative interpretation of the right to
health by the UN Committee on Economic, Social, and Cultural Rights, establishes that gov-
ernments have the ‘core obligation’ to provide essential medicines and to establish a national
health strategy and plan of action. [16] Given that a NMP is a country-wide strategy for the
pharmaceutical sector for the provision of essential medicines, State parties can be understood
as having a legal obligation to establish and implement a NMP or similar policy. The right to
health establishes universal minimum entitlements to essential medicines for all, a set of State
duties and guiding principles for government action (i.e. transparency and participation), and
mechanisms for rights enforcement and redress.
A right to health analysis of national medicines policies of 71 countries for universal health coverage
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Gaps in existing evidence
Despite the breadth of WHO’s 2001 guidelines, little evidence exists about integrating essential
medicines components and right to health commitments in existing NMPs. [4] The largest
cross-national comparison of NMPs examines their effectiveness and uptake in 64 mostly
LMICs, using national indicators for quality use of medicines. [8] Other analyses are single-
country or regional studies comparing NMPs against WHO’s essential medicines policies
without large-scale cross-national comparisons. [17–19] No earlier studies have assessed the
presence of right to health principles in NMPs.
An updated online repository of NMPs has only recently been established. NMPs are gener-
ally published in English or the national language, and were only available in hard copy or on
local websites. Earlier policy studies therefore mostly relied on governments’ self-reports in the
WHO Pharmaceutical Sector questionnaire of having a NMP or of its contents with binary
(yes/no) answers. [8,18] In 2016 the Lancet Commission on Essential Medicines Policies
undertook a first global search for all NMPs and later made them available to the WHO Essen-
tial Medicines Portal, which now provides easy access to these primary sources. [6]
Our article presents a first cross-national content analysis of essential medicines and right
to health principles for access to medicines in 71 NMPs. Our comparison of NMPs also identi-
fies some examples of strong text in support of universal access to medicines. These examples
can inform policy makers who are developing and revising NMPs in the era of UHC and a
strengthened right to health.
Materials and methods
A detailed description of the methodology is in the online S1 Appendix.
Data collection
Between January to October 2015 we conducted a systematic search of all NMPs mentioned in
academic literature, published in online repositories and on government websites, and further
expanded through a global call through the E-DRUG online network and targeted individual
approaches. We included one official NMP per country. We excluded draft, incomplete, and
unclear medicine policy documents, policies addressing a specific component (i.e. intellectual
property management), and documents in other languages besides English, Dutch, French, or
Spanish. This method, previously reported in Wirtz et al., yielded 67 full text NMPs, which
were deposited in WHO’s online Essential Medicines and Health Products Information Portal
(publicly accessible here: http://apps.who.int/medicinedocs/en/). [5] Between January 2017 to
March 2018 we were able to identify 13 additional full text NMPs that met the inclusion
criteria.
We recorded the year of the country’s most recent official NMP and its World Bank income
category in the year of publication.
Policy checklist
To analyse and assess the content of the NMPs, we developed a policy checklist by extracting
the relevant principles for medicines affordability and financing from WHO’s policies for
essential medicines, and from international human rights law. [2,4,13,16,20–22] These human
rights documents were chosen because they list the provision of essential medicines as a core
obligation or elaborate on the nature of State duties.
The policy checklist identifies 12 specific attributes of policy text for access to medicines
and rates their strength on a 3-point scale (see Table 1). We (SKP, NVA) identified the 12
A right to health analysis of national medicines policies of 71 countries for universal health coverage
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principles by first selecting a short list of concepts related to medicines affordability and
financing from the above documents. We categorised the 12 principles into three domains (see
Table 1 and the online S1 Appendix for a full description of the domains and principles): legal
rights and obligations (i.e. government’s commitments and duties), good governance (i.e. gov-
ernance principles and processes), and technical implementation (i.e. policy measures to
achieve government objectives). The domains correspond to the structure-process-outcome
framework for monitoring and evaluating the realisation of human rights. [23]
Table 1. Policy checklist for access to medicines in NMPs.
Checklist Human rights principle WHO essential medicines policy
Legal rights and obligations
1. Right to health Right to the highest attainable standard of health Human rights are a ‘value’. [2]
2. State obligation to
provide essential medicines
Core obligation to provide essential medicines defined by WHO
Good governance
3. Transparency Transparency Includes information to assess service access and coverage, and
publicly available price information for medicines. [1,3] Also a
component of good governance for medicines. [12]
4. Participation &
consultation
Participation Collaboration and accountability of all health systems actors, and
stakeholder consultation. [1,3] Also vaguely referenced in good
governance for medicines. [12]
5. Monitoring & evaluation Monitoring Achieved through explicit government commitment, indicator-
based surveys, and independent impact evaluation. [1,3] Also a
component of good governance for medicines. [12]
6. Accountability & redress Accountability Accountability of all health systems actors. [1] Also vaguely
referenced in good governance for medicines. [12]
Technical implementation
7. Selection of essential
medicines
(Assured) quality of health services (of the AAAQ) Includes the essential drugs concept, procedures to define and
update the national list(s) of essential drugs, explicit, evidence-based
criteria that includes cost-effectiveness, and selection mechanisms.
[3,11]
Duty to adopt appropriate legislative, administrative, budgetary
and other measures to a maximum of its available resources
Core obligation to provide essential medicines as defined by
WHO8. Government financing Requires adequate funding and mobilising all available public
resources and increase funding for priority diseases, and the
vulnerable. [1,3,11]
9. Pool user contributions Medicines reimbursement with user charges is a (temporary)
financing option. [1,11]
10. International assistance
and technical cooperation
Duty to seek international assistance and technical cooperation Includes the possibility of using development loans for medicines
financing. [11]
11. Efficient and cost-
effective spending
Duty for the efficient use of available resources
Duty to take appropriate steps to ensure that the private business
sector is aware of, and consider the importance of, the right to
health in pursuing their activities.
Duty to prevent unreasonably high costs for access to essential
medicines from undermining the rights of large segments of the
population to health.
Duty to seek low-cost policy options.
Includes the efficient use of resources and affordable pricing
through: price control; a pricing policy for all medicines;
competition through generic policies and substitution; good
procurement practices; price negotiation and information; and
TRIPs-compliant measures such as compulsory licensing and
parallel imports. [1,3,11]
12. Financial protection of
vulnerable groups
Duty towards non-discrimination and attention to the vulnerable Increase government funding for poor and vulnerable groups and
reduce the risk of catastrophic health spending. [1,11]
Abbreviations used in this table: WHO = World Health Organization; TRIPs = Trade Related Aspects of Intellectual Property; AAAQ = Availability, Accessibility,
Acceptability, and Quality as elements of health services under the right to health.
Through multiple, iterative rounds, we (SKP, NVA) independently piloted the short list on three NMPs and devised a 3-point coding matrix (see online S1 Appendix).
After each round we revised the principles and coding matrix through consensus. The resulting framework was reviewed by three experts on the right to health and
pharmaceutical policy (BT, HVH, EtH) for applicability to NMPs and accuracy of the definitions.
https://doi.org/10.1371/journal.pone.0215577.t001
A right to health analysis of national medicines policies of 71 countries for universal health coverage
PLOS ONE | https://doi.org/10.1371/journal.pone.0215577 June 28, 2019 4 / 15
We calculated the reliability of NMP text selection by two coders using Cohen’s Kappa.
SKP and NVA each independently coded six randomly selected countries (approx. 8% of the
sample countries: Botswana, Ethiopia, Fiji, Malawi, Oman, Timor-Leste). We extracted the
same NMP texts in 75.7% of cases with a Cohen’s K = 0.695, which indicates that 69.5% of sim-
ilarities between coders were not due to chance (0.61<Cohen’s K<0.8 suggests ‘substantial’
agreement).
Data analysis
Given the substantial agreement between coders, we (SKP, NVA) worked with one half of the
NMPs each to extract the relevant text (through keyword and manual search) and coded the
strength of each principle in the NMPs on a three-point coding matrix (i.e. strong, weak, or
absent text, defined in the online S1 Appendix). Generally, strong text includes a clear State
commitment to a principle and an action (i.e. to adhere to the concept of essential medicines
and introduce a national selection committee) and where possible related to medicines afford-
ability and financing. Weak text includes vague commitments. All text selections and codes
were independently reviewed (by both SKP and NVA) who discussed any inconsistencies and
jointly agreed on the final codes. We report the frequency of each principle in NMPs and
describe the different approaches towards each principle in different countries.We hypothe-
sised that the content of WHO’s 2001 NMP guidelines would inform the content of subse-
quent NMPs. Therefore we divided NMPs between those adopted in or before 2003 (n = 32)
and those adopted in or after 2004 (n = 39). Associations were determined in SPSS version 25
using Pearson’s Chi-squared statistic with significance set at p<0.05.
Results
Of the 80 full text NMPs we intitally retrieved, nine were excluded due to language restrictions
or incompleteness. We included 71 NMPs published between 1990 and 2016. Our sample has
a higher proportion of NMPs published before 2004 (�2003 n = 32/47, 68% vs.�2004 n = 39/
88, 44%) and by low income countries (n = 35/46, 76%) than middle and high income nations
(n = 35/132, 27%).
The essential medicines and human rights principles included in each NMP are presented
in Table 2. No NMP includes all of the 12 principles. NMPs with examples of innovative ideas
are listed in Table 3 and the full text of these examples is available in the online S2 Appendix.
The following sub-sections highlight the most relevant descriptive data for each principle.
12 principles for access to medicines in NMPs
1. Right to health. Eleven NMPs frame access to medicines as part of the right to health
(Congo 2004, Bhutan 2007, Kenya 2008, Colombia 2012, El Salvador 2011–2014, Kyrgyzstan
2014, Uganda 2015, Philippines 2011–2016, Rwanda 2016) and/or a right that governments
must ensure (South Sudan 2006, Seychelles 2009). Kenya (2008) references the ICESCR and
Colombia (2012) cites General Comment No. 14.
2. State obligation. Access to medicines as a State obligation is mentioned in Syria (1992),
Tajikistan (2003), Iran (2004), Indonesia and South Sudan (2006), El Salvador (2011–2014),
Kyrgyzstan (2014), and the Philippines (2011–2016). Uganda (2015) requires the government
to progressively realise UHC with essential services. Four NMPs (Congo 2004, Maldives 2007,
Suriname 2005–2008, Timor Leste 2010) frame the government as being responsible for con-
tinuous medicines availability at an affordable price. The State must ensure the availability of
medicines for all in need (South Africa 1996). Bhutan (2007) and Sudan (2005–2009) require
A right to health analysis of national medicines policies of 71 countries for universal health coverage
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the State to establish mechanisms to guarantee access for all to the medicines they need at an
affordable price.
3. Transparency. Eighteen NMPs mention the principle of transparency in relation to
medicines prices, cost, or affordability. Notable examples reinforce the transparency of medi-
cines selection and procurement (Malaysia 2012), funding decisions (New Zealand, 2007),
pricing (Philippines 2011–2016), price information sharing including with the public (Philip-
pines, Malaysia) and through a price database (Malaysia).
4. Participation and consultation. South Africa (1996) and New Zealand (2007) include
public participation in matters of medicines pricing and affordability.
5. Monitoring and evaluation. Monitoring medicines prices serves to compare and
widen tenders (Oman 2000), benchmark for setting domestic prices (Iran 2004), contain price
increases (Malaysia 2012), to monitor affordability (South Sudan 2006), cost-efficiency and
acceptability (Afghanistan 2014), or to determine the effects of international trade agreements
on domestic access to medicines (Nigeria 2005). Monitoring is done by the Pricing Committee
(Somalia 2013) or through a database (South Africa 1996) or an electronic essential medicines
monitoring system (Philippines 2011–2016). Uganda (2015) frames monitoring progress
towards equity and efficiency as part of the progressive realisation of the right to health. Tajiki-
stan (2003) presents a robust list of indicators and Barbados (1999) adopts the indicators of the
Harvard Drug Policy Research Group and Management Sciences for Health.
6. Accountability. No NMP describes accountability in relation to medicines affordability
or financing. The general principle of accountability is applied to medicines procurement
(Pakistan 1997, Bhutan 2007), distribution (Botswana 2002), and financial management
Table 3. Innovative NMP text for access to medicines.
1. Right to health including essential medicines
El Salvador (2011)—Southern Sudan (2006)
2. State duty to provide pharmaceuticals
Indonesia (2006)—Iran (2004)—Philippines (2011–2016)—Uganda (2015)
3. Transparency of governments’ action and outcomes for medicines affordability
Iran (2004)—Philippines (2011–2016)
4. Participation and consultation for medicines affordability
New Zealand (2007)
5. Monitoring and evaluation for medicines affordability
Colombia (2012)—Philippines (2011–2016)—Tajikistan (2003)
6. Accountability and redress for medicines affordability
Afghanistan (2014)—Kenya (2008)—Malaysia (2012)
7. Selection of essential medicines
Philippines (2011)—South Africa (1996)
8. Sufficient government financing for essential medicines
Afghanistan (2014)—Nigeria (2005)
9. Pooling user contributions for essential medicines
Eritrea (2010)
10. International assistance and technical cooperations for medicines affordability
Ecuador (2007)—Ghana (2004)
11. Efficient and cost-effective spending on essential medicines
Ecuador (2007)
12. Financial protection of the poor and vulnerable
Jordan (2014)—Philippines (2011–2016)—Timor Leste (2010)
https://doi.org/10.1371/journal.pone.0215577.t003
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(Seychelles 2009, Swaziland 2011). Specific accountability mechanisms for general medicines
issues are recognised in Kenya (2008), Malaysia (2012), and the Philippines (2011–2016).
7. Medicines selection. Three NMPs indicate that the national essential medicines list
(EML) serves as a basis for UHC (Uganda 2015) or reimbursement (Namibia 1998, Philippines
2011–2016). Frequent references are to the selection procedure (i.e. committee composition,
periodicity of list, n = 40), the selection criteria (n = 27), or to the concept of essential medi-
cines and/or the WHO Model List of Essential Medicines (n = 20). Less frequent was an expla-
nation of the use or the purpose of an EML within the national health system (n = 15).
Comprehensive NMPs that address multiple aspects of the selection of essential medicines are
South Africa (1996), Pakistan (1997), Namibia (1998), Oman (2000), Nigeria and Iraq (2005),
Maldives (2007), Malaysia (2012), Somalia (2013), and El Salvador (2011–2014).
8. Government financing. Frequent references to government financing are for the provi-
sion of sufficient or adequate funding (n = 14) and to base medicines procurement and provi-
sion on objective health needs (n = 13). Less frequent is the duty of governments to dedicate
funding to priority populations, priority diseases, or essential medicines (n = 7), to increase
funding for medicines (n = 6) or to find alternate funding sources (n = 4).
Only Guinea (1994) and Indonesia (2006) set a quantitative threshold for government
financing. In Guinea, the government spending target is US$ 0.25/inhabitant/year to finance
‘social medicines’ such as vaccines, anti-leprosy medicines and tuberculosis medicines. In
Indonesia, a financing target must be set considering WHO’s then recommended minimum
allocation of US$ 2.00/capita.
9. Pooling user contributions. No NMP includes the principle of universal financial pro-
tection for users nor the compulsory pre-payment of contributions (usually through health
insurance). The most comprehensive language is from South Africa (1996), Eritrea (2010) and
Somalia (2013), which provide for free or low-cost access to medicines in primary care, and
user contributions to finance medicines in secondary and tertiary care, with exceptions for
people unable to pay. Botswana (2002) and Fiji (2013) adopt these principles as well, but with-
out mentioning specific levels of care. A long-term objective in some NMPs was to develop
health insurance and medicines reimbursement, e.g. in Namibia (1998), Tajikistan (2003), and
Sri Lanka (2006).
10. International assistance and technical cooperation. Ten NMPs describe assistance
from the international community to promote the affordability of medicines. Assistance takes
the form of technical cooperation and partnership for medicines accessibility (Malaysia 2012);
bilateral and multilateral aid for essential medicines programmes (Gabon 1999, Democratic
Republic of Congo 2002, Congo 2004); the financing for the public sector (Ghana 2004); mobi-
lising resources for new essential medicines (Afghanistan 2014); reference pricing policies and
price information exchange (Ecuador 2007); the negotiation of prices at sub-regional level
(ANDEAN) and the exchange of information to prevent monopolistic practices (Peru 2004);
to establish a donor coordination mechanism to document the finances used in procurement
(Swaziland 2011). Colombia (2012) calls for the development of an interagency agenda for
‘health diplomacy and access to medicines’ that would include a National Health Technology
Assessment to exchange methods, information, and capacities with national and international
networks of experts.
11. Efficient spending. Many NMPs describe various policy measures to achieve generic
promotion (n = 37), pricing policies (n = 30), the use of flexibilities to Agreement on Trade-
Related Aspects of Intellectual Property (TRIPS) and other measures to manage intellectual
property (n = 21), tax exemptions (n = 16), pooled procurement (n = 8), price transparency
(n = 7), and price negotiation (n = 7). NMPs that apply multiple, complementary policy mea-
sures are South Africa (1996), Ghana and Iran (2004), Nigeria (2005), Indonesia and South
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Sudan (2006), Ecuador (2007), the Seychelles (2009), Cambodia (2010), El Salvador (2011–
2014), Jordan (2014), and the Philippines (2011–2016).
12. Protection for the poor and vulnerable. Eighteen NMPs refer to medicines afford-
ability or financing for specific populations such as children, people in remote or mountainous
locations, ethnic groups, women, the disabled, or people with ‘priority diseases’ defined as
tuberculosis, HIV, or malaria. Nine NMPs refer to medicines provision for general ‘vulnerable’
groups.
Trend analysis. Compared to WHO’s 1988 guidelines, the 2001 policy guidelines intro-
duce strong commitments to individual rights, transparency, and measures for efficiency and
cost-effectiveness, for pooling user contributions, for international cooperation, and for finan-
cial protection of the poor and vulnerable. Recommendations for medicines selection and gov-
ernment financing are strong in both WHO’s 1988 and 2001 guidelines.
Several trends are visible between NMPs published before or after 2004, including strong
commitments to individual rights (�2003: n = 0/32 (0%) vs.�2004: n = 13/39 (33%),
p = 0.000), measures for government financed-medicines (6/32 (19%) vs 18/39 (46%),
p = 0.015), for efficiency and cost-effectiveness (14/32 (44%) vs 29/39 (74%), p = 0.009), and
for financial protection of the poor and vulnerable (4/32 (13%) vs 13/39 (33%), p = 0.041).
Discussion
This paper presents a first cross-national comparison of the most recent NMPs from 71 coun-
tries, published between 1990–2016, using a 12-point checklist for universal access to medi-
cines based on human rights and health system principles. The selection of essential medicines
and their cost-effectiveness are the most frequent policy measures in our sample of NMPs.
Good governance (transparency, participation, monitoring, or accountability for medicines
affordability and financing), and measures to pool user contributions and to seek international
cooperation remain weak or absent. An individual right to health, and measures for govern-
ment financing of essential medicines, cost-effective spending, and financial protection of
vulnerable groups are significantly stronger in NMPs published after 2004 than in those pub-
lished before. NMPs with the clearest and strongest commitments to essential medicines and
human rights principles are from South Africa (1996), Indonesia and South Sudan (2006),
Malaysia (2012), Somalia (2013), Afghanistan (2014), Uganda (2015), and the Philippines
(2011–2016); these texts may serve as models for others.
Historical trends
Our findings suggest that some aspects of WHO’s 2001 guidelines were instructive and
impactful on national pharmaceutical policy processes. Strong principles introduced in
WHO’s 2001 guidelines are significantly more frequent in NMPs adopted in 2004 or later (i.e.
an individual right to health, measures for cost-effective spending, and financial protection of
vulnerable groups). Transparency is also significantly more common (although not always in
relation to medicines affordability and financing) in NMPs adopted after 2003. Some impor-
tant principles in WHO’s 2001 guidelines, such as measures to pool user contributions and to
seek international cooperation, have rarely been taken up by any country. We cannot draw
firm conclusions about the causal relation between WHO’s 2001 guidelines on NMP content,
and subsequent national policies. We examined only the most recent NMP per country and
cannot discount the possibility that certain countries already embraced the 12 principles in
previous NMPs. Paired examples are rare: even our most up-to-date collection of all available
NMPs only has the full text of NMPs before and after 2004 from four countries (Afghanistan,
Colombia, Kenya, Uganda). The example of Kenya shows that legal rights or obligations
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appear in its 2008 NMP and not in its 1994 NMP. Conversely, both of Colombia’s 2003 and
2012 NMPs advocate for medicines as social goods, articulate health as a fundamental right,
and promote measures to control medicines pricing.
Implications for national pharmaceutical policy
Our basic hypothesis is that a NMP that explicitly identifies our 12 policy measures has the
potential to address inequitable access to essential medicines by refocusing government pol-
icy and programmes on the medicines needs of the most vulnerable populations. Evaluating
this hypothesis is difficult because few studies have examined the impacts of NMP provi-
sions on medicines financing and affordability impacts on vulnerable populations. It is
important to keep in mind that measuring the impact of a national policy is methodologi-
cally difficult as a control group is never possible. The next best methods are longitudinal
time-series analyses, and observational studies which are often only post-intervention; but
these methods do not allow for a reliable assessment of policy impact or causality. [24] One
cross-sectional study of 64 NMPs by Holloway et al. identified a significant association
between having a NMP (regardless of its content) and the provision of free medicines, a
supply-side measure. [8] In another example, Colombia’s 2012–2021 National Pharmaceuti-
cal Policy promotes efficient spending on medicines through external reference pricing
(among other measures), which was indeed implemented in 2013. [25,26] An impact study
of the best selling 90 medicines suggests that this external reference pricing policy achieved
a decrease in prices between 2011–2015, although sales and spending increased in the same
period. [26] It is very likely that the external reference pricing system had an impact on the
government’s capacity to finance medicines for vulnerable groups, but the causal relation
cannot be proven.
Public financing and affordability of essential medicines for vulnerable groups has only
been framed as a right in WHO’s NMP guidelines of 2001. Framing in health policy is gaining
increasing attention as a means to reorient public health debates, the perception of problems,
and their plausible solutions. [27] In our study, framing medicines as part of the right to health
moves the debate away from which patients can afford health commodities, towards the ques-
tion of how governments can provide basic essential goods to everyone, based on the common
respect for the human dignity of all people. Human rights framing also implies certain obliga-
tions, such as the minimum core obligation of governments to provide essential medicines to
those who can not provide for themselves. [16] Finally, a rights-based lens implies a certain set
of principles towards achieving universal access to essential medicines, such as non-discrimi-
nation in medicines provision, maximising available government resources, seeking interna-
tional assistance and cooperation, and selecting low-cost/most efficient policy options. [28] An
example of human rights framing is found in the Philippines’ constitution, its 2011–2016
NMP, and national legislation for medicines. These documents all affirm the government’s
duty to “make essential goods, health, and other social services available to all people at an
affordable cost,” and guide national health insurance programmes for access to medicines.
[29–31] Indeed, the 2011–2016 Philippine NMP and related national legislation for universal
health coverage promotes government financing for essential medicines, efficient spending on
medicines through cost-effectiveness measures, and guaranteed financial protection for vul-
nerable groups to access medicines. [10] Unfortunately, little data is available to concretely
assess the ultimate impact of these measures on patient affordability and access.
The debate around indication-based pricing (i.e. different prices for different indications of
the same medicine) is ongoing. From the human rights perspective, it is important that gov-
ernments ensure medicines prices do not preclude access to essential medicines for patients.
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As with all governmental pricing policies, States should regularly monitor, evaluate, and report
on the level of patient access, and remedy barriers when they occur.
We suggest that the innovative ideas and example texts identified in this article (Table 3
and online S2 Appendix) may form the basis of a balanced commitment to medicines afford-
ability and financing in NMPs. We recommend that NMPs should address each of the 12 prin-
ciples to find the right balance between the government’s duties as the primary funder of public
sector pharmaceuticals, as the coordinator of all revenues (including user contributions and
international funding), and as the steward of medicines selection, procurement and pricing.
Implications for WHO policy
Updating WHO’s 2001 guidelines on NMPs and aligning them with WHO’s latest policies on
essential medicines and human rights law will raise Member States’ awareness of the impor-
tance of human rights, their legal obligations, and the available policy measures to implement
these duties in practice. Moreover, official WHO guidance on how to address UHC and
embed the right to health in NMP text, with specific examples, can support ongoing national
reforms or trigger other initiatives for universal access to essential medicines. Ultimately,
enhanced legal commitments and political can catalyse inclusive progress towards universal
access to essential medicines and the SDG for health.
How should WHO’s guidelines be revised? We recommend that WHO’s updated NMP guide-
lines should address critical gaps by explicitly referencing the State duty to provide essential medi-
cines to those who need them, the participation of beneficiaries in medicines policy, and the
creation of (non-judicial) accountability and redress mechanisms. If appropriately implemented,
enhanced accountability and redress mechanisms, such as easy-to-access complaint and grievance
procedures for patients, have the potential to swiftly remove access barriers. [32]
These mechanisms could also help stem the wave of spurious human-rights based litigation
rising in some Latin American countries where many court cases claim access to publicly-
funded, high-priced medicines using the misguided argument that the right to health entails
immediate access to any treatment regardless of its price. [33–36] In previous work the authors
have identified trends in UHC legislation for access to medicines. [10] We suggest that these
same strategies could be embedded in NMPs to avoid deleterious medicine litigation; these
trends are: articulating clear patient rights to access medicines proven to be cost-effective, and
ensuring efficient and effective complaints procedures.
Implications for research
Future research should investigate whether and how the commitments in NMPs are imple-
mented in government practice. More investigation is also needed to determine the effective-
ness of rights-based medicines policies at improving medicines affordability and equitable
access for patients, and what the practical facilitators and barriers to implementation are.
Strengths and limitations
Although our NMPs are sourced from the most comprehensive collection to date, our sample
has more NMPs published before 2004, and from low-income countries. Retrieving few full-
text NMPs from higher-income countries may be caused by governments self-reporting ‘yes’
in the WHO Pharmaceutical Sector questionnaire despite not having an official NMP (i.e.
Mexico) or having a medicine law which functions as a NMP (i.e. Morocco). In some cases the
full text of an official NMP was neither retrievable online nor through crowdsourcing in the E-
drug network or targeted individual approaches.
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We mitigated the risk of overlooking relevant policy content in our analysis by working
with researchers fluent in the original language of the NMP and trained on the structure, stan-
dard terminology, and definitions used in the WHO guidelines and our checklist.
Conclusion
Our study demonstrates to which extent a human rights-based approach to access to essential
medicines within UHC schemes is integrated into 71 most recent NMPs, using a 12-point
checklist focusing on medicines affordability and financing for vulnerable groups. Specific
examples of how essential medicines and human rights principles are phrased in NMPs can be
used by WHO and national policy makers to further align the goals and strategies of the
national pharmaceutical sector with human rights law and the SDG targets for universal access
to essential medicines.
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